Furthermore, combining p53 therapies with up-and-coming immunotherapies, such as adoptive T-cell transfer, oncolytic virus immunotherapy, cancer vaccines, and immune checkpoint inhibitors, are attractive approaches as they could target both the intrinsic and extrinsic apoptotic pathways, inducing cancer cell death from a multitude of angles [180,181]. This evidence concerns the gene TP53 and cancer.